PRN Archives - Page 2 of 8

Markets

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...

June 5, 2023

Developments

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...

June 2, 2023

Developments

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET. The...

May 30, 2023

Developments

Profound Medical’s TULSA procedure featured at AUA

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...

May 1, 2023

Developments

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

Y. Mark Hong, M.D., a key opinion leader (KOL) and world recognized urologist, suggests that if physicians aren’t offering or at least talking to their prostate cancer patients about Profound Medical’s (NASDAQ:PROF;...

April 11, 2023

Developments

Profound Medical CEO adds to holdings, again

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired 13,000 shares of the company at a price of $7.81 (U.S.) each on the open market to hold 425,296 shares...

December 21, 2022

Markets

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James analyst, Rahul Sarugaser, Ph.D., outlined a series of potential catalysts for Profound Medical (NASDAQ:PROF; TSX:PRN), through 2023 and 2024 as it continues to commercialize its TULSA-PRO medical device to...

December 19, 2022

Developments

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

UT Southwestern in Dallas, one of the nation’s premier academic medical centers, performed its 100th procedure with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO, an innovative MRI-guided minimally invasive...

December 9, 2022

Developments

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

An investigator for Profound Medical (NASDAQ:PROF; TSX:PRN) presented four-year follow-up data from the TACT clinical study with Profound’s TULSA-PRO device that continue to demonstrate durable and stable safety and...

September 26, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Tag - PRN

Research Capital ups Profound Medical to speculative buy; PT to $17.25

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Profound Medical’s TULSA procedure featured at AUA

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

Profound Medical CEO adds to holdings, again

Raymond James sees catalyst-rich two years ahead for Profound

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

Profound Medical realigns commercial organization to support continued growth

General

More